References
- Johns Hopkins Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020. [cited 2022 May 3]. https://coronavirus.jhu.edu/map.html
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826.
- Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020;383(21):2041–2052.
- Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393.
- Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases - borrowing from History. N Engl J Med. 2018;378(16):1469–1472.
- Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124.
- Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. N Engl J Med. 2021;385(15):1382–1392.
- Kwenandar F, Japar KV, Damay V, et al. Coronavirus disease 2019 and cardiovascular system: a narrative review. Int J Cardiol Heart Vasc. 2020;29:100557.
- Gawałko M, Kapłon-Cieślicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc. 2020;30:100631.
- Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818.
- Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Heart Rhythm. 2020;17(9):e233–e241.
- Taha ME, Alsafi W, Taha M, et al. Coronavirus disease and new-onset atrial fibrillation: two cases. Cureus. 2020;12(5):e8066.
- US Food and Drug Administration. Fact sheet for health care emergency use authorization (EUA) of bamlanivimab and etesevimab. FDA. 2021. [cited 2021 Dec 2]. https://www.fda.gov/media/145802/download
- Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644.